DNA Nanotechnology for Cancer Therapeutics
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
DNA nanotechnology is an emerging and exciting field, and represents a forefront frontier for the biomedical field. The specificity of the interactions between complementary base pairs makes DNA an incredible building material for programmable and very versatile two- and three-dimensional nanostructures called DNA origami. Here, we analyze the DNA origami and DNA-based nanostructures as a drug delivery system. Besides their physical-chemical nature, we dissect the critical factors such as stability, loading capability, release and immunocompatibility, which mainly limit in vivo applications. Special attention was dedicated to highlighting the boundaries to be overcome to bring DNA nanostructures closer to the bedside of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 2×
“shown to enhance permeability and retention (EPR) effects, leading to passive tumor drug accumulation [1].”
BackgroundGilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948 · cited 2×
“Multiple cell signaling effectors are utilized for nanoparticle cellular internalization but gene knockdown effects are almost abrogated by recycling pathways with specific proteins involved in the process [96].”
BackgroundHaran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934 · cited 1×
“An active remote loading was developed that works perfectly with doxo and could be utilized for weak basic or acid amphipathic molecules [93].”
BackgroundDNA nanotechnology from the test tube to the cell
Chen, Y.-J., Groves, B., Muscat, R. A., & Seelig, G. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.195 · Cited by 594 · cited 1×
“Recently, many research groups have focused their attention on DNA material for the construction of artificial nanostructures not present in biological systems for bio-applications [5–8].”
BackgroundRapid Folding of DNA into Nanoscale Shapes at Constant Temperature
Sobczak, J.-P. J., Martin, T. G., Gerling, T., & Dietz, H. (2012) · Science · doi:10.1126/science.1229919 · Cited by 285 · cited 2×
“Many laboratories are working in this direction and some improvements were recently achieved [46,105,106].”
Background
Cited by
The History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine
Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M., & Rizzolio, F. (2019) · Molecules · doi:10.3390/molecules25010112 · Cited by 2,016
Self-citationSupramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Komiyama, M., Yoshimoto, K., Sisido, M., & Ariga, K. (2017) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20170156 · Cited by 296
Rationally Engineered Nucleic Acid Architectures for Biosensing Applications
Xiao, M., Lai, W., Man, T., Chang, B., Li, L., Chandrasekaran, A. R., & Pei, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00121 · Cited by 290
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
“These delivery systems offer several advantages such as highly-controlled release with addressable modification sites, simple loading of drugs, resistance against enzymatic degradation, biocompatibility and biodegrade ability compared to other delivery systems which have already been approved for clinical use [62].”
Background
Metadata
- Authors
- Kumar, V., Palazzolo, S., Bayda, S., Corona, G., Toffoli, G., & Rizzolio, F.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2016
- Volume
- 6
- Issue
- 5
- Pages
- 710-725
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2312557846
- Cited by
- 147
- References
- 7
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.